Tyenne Injection, Solution, Concentrate
Product Images NDC 65219-590

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Tyenne (NDC 65219-590). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Fresenius Kabi Usa, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Tocli-img-01.jpg (Tocil Img 01)

A line graph depicting percentage (%) of ACR20 responders over time (weeks 2 to 24) in three treatment groups: Placebo + MTX (N=204) shown with circles, Tocilizumab 8 mg/kg + MTX (N=208) shown with triangles, and Tocilizumab 4 mg/kg + MTX (N=213) shown with squares. The y-axis shows percentage response with error bars, and the x-axis shows visit weeks. Tocilizumab 8 mg/kg + MTX group shows the highest response rates throughout the study period.*

FDA Label Image

Tocli-img-02.jpg (Tocil Img 02)

A forest plot displaying risk differences with 95% confidence intervals for mortality across four studies comparing Tocilizumab plus standard of care (SOC) to SOC alone. It includes study names (COVACTA, EMPACTA, REMDACTA, RECOVERY), number of participants, death counts and percentages for each group, and an overall summary risk difference shown with a diamond symbol.*

FDA Label Image

Tocil-label-01.jpg (Tocil Label 01)

Packaging label for TYENNE injection, an intravenous solution concentrate of Tocilizumab-aazg with a strength of 80 mg/4 mL (20 mg/mL) by Fresenius Kabi USA, LLC. The carton contains 1 single-dose vial and includes prescribing information and a medication guide. Label includes storage instructions and inactive ingredient details.*

FDA Label Image

Tocil-label-02.jpg (Tocil Label 02)

Label for TYENNE (tocilizumab-aazg) injection, concentrate, 80 mg / 4 mL (20 mg/mL) for intravenous infusion. The label includes NDC 65219-590-04, states Rx only, and displays the manufacturer as Fresenius Kabi USA, LLC. The label also shows a barcode, a lot and expiration date area, and a QR code.*

FDA Label Image

Tocil-label-03.jpg (Tocil Label 03)

Packaging label for TYENNE Tocilizumab-aazg Injection, 200 mg/10 mL (20 mg/mL) concentrate for intravenous infusion. The carton includes 1 single-dose vial, prescribing information, and medication guide. Manufactured by Fresenius Kabi USA LLC, the label indicates storage instructions and ingredients including inactive components. It advises to refrigerate immediately and not use if the seal is broken or missing.*

FDA Label Image

Tocil-label-04.jpg (Tocil Label 04)

Label for TYENNE injection, containing tocilizumab-aazg at 200 mg/10 mL concentration (20 mg/mL). The label specifies it is for intravenous infusion and dilution is required before use. The labeler is Fresenius Kabi USA, LLC, with their logo and US license number 2146 also visible.*

FDA Label Image

Tocil-label-05.jpg (Tocil Label 05)

Carton label for TYENNE Tocilizumab-aazg Injection, 400 mg/20 mL (20 mg/mL) concentrate for intravenous infusion. The packaging includes usage instructions, storage information, and a carton contains 1 single-dose vial with prescribing and medication guides. Labeler is Fresenius Kabi USA, LLC, with manufacturing in Austria. Barcode and lot/expiration details are also visible.*

FDA Label Image

Tocil-label-06.jpg (Tocil Label 06)

Label for TYENNE (tocilizumab-aazg) injection, 400 mg/20 mL (20 mg/mL) concentrate for intravenous infusion. The label indicates Rx only and includes the NDC 65219-594-20. It is manufactured by Fresenius Kabi USA, LLC. The label also shows barcode, lot, and expiration date fields.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.